Encage is a breakthrough in treatment for prostate cancer, one of the most common soft tissue cancers in the world with around 240,000 new cases every year in the US alone. As the lead Medtech product in question, it has the potential to reduce the risk of side effects commonly associated with current treatments, including erectile dysfunction (impotence), and urinary and fecal incontinence.
The Encage device therefore represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.
TROD Medical is a VC-backed company with two co-leads founded in 2006 by Andre Faure, Capricorn Venture Partners (Belgium) and Vesalius Biocapital (Luxembourg). The Company is headquartered in Leuven (Belgium) and has facilities in the Tampa Bay area (US), and Paris (France).
As Faure explained,